Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

58 recalls, newest first

Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1001-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1000-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-0999-2020
Class III · Low risk

Discount Drug Mart

Labeling: Incorrect or Missing Lot and/or Expiration date.

Terminated Labeling / mix-up AAA Pharmaceutical, Inc. NDC 53943-192-04 D-0868-2020
Class III · Low risk

TRAMADOL HYDROCHLORIDE Tablets

Labeling: Incorrect package insert - Patient leaflets for the specified lots of unscored tablets contain language relative to a 25 mg dosing titration that necessitates the use of a scored 50 mg tablet.

Terminated Labeling / mix-up Golden State Medical Supply Inc. NDC 60429-588-01 D-0856-2020
Class III · Low risk

Frovatriptan Succinate Tablets

Labeling: Incorrect or Missing Lot and/or Exp Date: Product incorrectly labeled with an expiration date of August 2022 rather than the correct expiration date of April 2022.

Terminated Labeling / mix-up Par Pharmaceutical Inc. NDC 0603-3718-34 D-0843-2020
Class III · Low risk

Tramadol Hydrochloride Tablets USP CIV

Labeling: Incorrect package insert - Patient leaflets for the specified lots of unscored tablets contain language relative to a 25 mg dosing titration that necessitates the use of a scored 50 mg tablet.

Terminated Labeling / mix-up Teva Pharmaceuticals USA NDC 0093-0058-01 D-0851-2020
Class III · Low risk

methylPREDNISolone Sodium Succinate For Injection

Labeling: Incorrect Instructions: Vial label incorrectly instructs healthcare professional to reconstitute product with 16 mL rather than the correct volume of 8 mL of Bacteriostatic Water for Injection with Benzyl Alcohol.

Terminated Labeling / mix-up Hikma Pharmaceuticals USA Inc. NDC 0143-9850-01 D-0801-2020

Recalls by year